Table 1 Baseline characteristics of patients with Urexel™
N = 12 | |
|---|---|
Age at surgery, year (range) | 61.5 (44–82) |
Sex, n (%) | |
Male | 3 (25) |
Female | 9 (75) |
Ureter units, n | 13 |
Location of ureteral obstruction, n (%) | |
Proximal | 1 (7.7) |
Distal | 1 (7.7) |
Proximal to middle | 3 (23.1) |
Proximal to distal | 2 (15.4) |
Middle to distal | 6 (46.2) |
Laterality, n (%) | |
Right | 8 (66.7) |
Left | 3 (25) |
Bilateral | 1 (8.3) |
Underlying cause of ureteric obstruction, n (%) | |
Colorectal cancer | 4 (33.3) |
Gynecologic cancer | 4 (33.3) |
Stomach cancer | 3 (25) |
Breast cancer | 1 (8.3) |
Previous percutaneous nephrostomy, n (%) | 4 (33.3) |
Unilateral | 4 (100) |
Previous double-J stent, n (%) | 7 (58.3) |
Unilateral | 6 (85.7) |
Bilateral | 1 (14.3) |
Preoperative creatinine, mg/dL (range) | 0.73 (0.53–3.41) |
Preoperative eGFR, mL/min/1.73m2(range) | 87.2 (14.8-119.1) |
Previous radiation history, n (%) | 8 (66.7) |
Length of obstruction, cm (range) | 9 (1–22) |
Total follow-up, months (range) | 25.5 (4–37) |